JP5227172B2 - デングウイルス感染に対するワクチン接種 - Google Patents
デングウイルス感染に対するワクチン接種 Download PDFInfo
- Publication number
- JP5227172B2 JP5227172B2 JP2008526124A JP2008526124A JP5227172B2 JP 5227172 B2 JP5227172 B2 JP 5227172B2 JP 2008526124 A JP2008526124 A JP 2008526124A JP 2008526124 A JP2008526124 A JP 2008526124A JP 5227172 B2 JP5227172 B2 JP 5227172B2
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- dengue
- virus
- yellow fever
- chimeric flavivirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010012310 Dengue fever Diseases 0.000 title claims description 187
- 208000025729 dengue disease Diseases 0.000 title claims description 178
- 238000002255 vaccination Methods 0.000 title description 46
- 208000001490 Dengue Diseases 0.000 claims description 172
- 229960005486 vaccine Drugs 0.000 claims description 162
- 241000710831 Flavivirus Species 0.000 claims description 119
- 241000700605 Viruses Species 0.000 claims description 92
- 101710132601 Capsid protein Proteins 0.000 claims description 57
- 101710094648 Coat protein Proteins 0.000 claims description 57
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 57
- 101710125418 Major capsid protein Proteins 0.000 claims description 57
- 101710141454 Nucleoprotein Proteins 0.000 claims description 57
- 101710083689 Probable capsid protein Proteins 0.000 claims description 57
- 241000710772 Yellow fever virus Species 0.000 claims description 55
- 229940051021 yellow-fever virus Drugs 0.000 claims description 55
- 108010052285 Membrane Proteins Proteins 0.000 claims description 44
- 102000018697 Membrane Proteins Human genes 0.000 claims description 42
- 230000028993 immune response Effects 0.000 claims description 29
- 241000725619 Dengue virus Species 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 17
- 229960001515 yellow fever vaccine Drugs 0.000 claims description 17
- 229940124926 Yellow fever virus vaccine Drugs 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 229940031351 tetravalent vaccine Drugs 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 7
- 230000002459 sustained effect Effects 0.000 claims description 7
- 229940031346 monovalent vaccine Drugs 0.000 claims description 6
- 230000007479 persistent immune response Effects 0.000 claims 1
- 229960004854 viral vaccine Drugs 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 description 150
- 238000000034 method Methods 0.000 description 49
- 230000003472 neutralizing effect Effects 0.000 description 42
- 230000003053 immunization Effects 0.000 description 21
- 238000002649 immunization Methods 0.000 description 21
- 230000005875 antibody response Effects 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 229940124928 YF-Vax Drugs 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 230000036039 immunity Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 206010058874 Viraemia Diseases 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 208000009714 Severe Dengue Diseases 0.000 description 11
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 11
- 210000003501 vero cell Anatomy 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 10
- 101000619564 Homo sapiens Putative testis-specific prion protein Proteins 0.000 description 9
- 101000708009 Homo sapiens Sentrin-specific protease 8 Proteins 0.000 description 9
- 102100022208 Putative testis-specific prion protein Human genes 0.000 description 9
- 102100031407 Sentrin-specific protease 8 Human genes 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000005867 T cell response Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 241000710815 Dengue virus 2 Species 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 230000002238 attenuated effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 230000002085 persistent effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 229920002477 rna polymer Polymers 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229940031418 trivalent vaccine Drugs 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102100034349 Integrase Human genes 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 101710172711 Structural protein Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940124590 live attenuated vaccine Drugs 0.000 description 4
- 229940023012 live-attenuated vaccine Drugs 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940031416 bivalent vaccine Drugs 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000710872 Dengue virus 3 Species 0.000 description 2
- 241000710829 Dengue virus group Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 201000005807 Japanese encephalitis Diseases 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 241000274177 Juniperus sabina Species 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000036878 aneuploidy Diseases 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000011018 current good manufacturing practice Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 210000000852 deltoid muscle Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002134 immunopathologic effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108091092236 Chimeric RNA Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011053 TCID50 method Methods 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940023605 dengue virus vaccine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70703805P | 2005-08-10 | 2005-08-10 | |
| US60/707,038 | 2005-08-10 | ||
| US71944805P | 2005-09-22 | 2005-09-22 | |
| US60/719,448 | 2005-09-22 | ||
| PCT/US2006/030846 WO2007021672A2 (en) | 2005-08-10 | 2006-08-09 | Vaccination against dengue virus infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009504654A JP2009504654A (ja) | 2009-02-05 |
| JP2009504654A5 JP2009504654A5 (enExample) | 2010-08-19 |
| JP5227172B2 true JP5227172B2 (ja) | 2013-07-03 |
Family
ID=37758084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008526124A Expired - Fee Related JP5227172B2 (ja) | 2005-08-10 | 2006-08-09 | デングウイルス感染に対するワクチン接種 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080193477A1 (enExample) |
| EP (1) | EP1924280A4 (enExample) |
| JP (1) | JP5227172B2 (enExample) |
| AR (1) | AR055603A1 (enExample) |
| AU (1) | AU2006280144B2 (enExample) |
| BR (1) | BRPI0614265A2 (enExample) |
| CA (1) | CA2618783A1 (enExample) |
| IL (1) | IL189329A (enExample) |
| MY (1) | MY151051A (enExample) |
| NO (1) | NO20081127L (enExample) |
| TW (1) | TW200740458A (enExample) |
| WO (1) | WO2007021672A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| NZ618158A (en) * | 2009-06-01 | 2015-05-29 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
| BRPI0904020B8 (pt) | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | composição vacinal contra o vírus da dengue, e, kit |
| WO2013151764A1 (en) * | 2012-04-02 | 2013-10-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for dengue virus epitopes |
| WO2014016362A1 (en) | 2012-07-24 | 2014-01-30 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| EP3932422A1 (en) | 2012-07-24 | 2022-01-05 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
| BR112015012515B1 (pt) | 2012-11-30 | 2023-04-11 | Sanofi Pasteur | Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola |
| CA2933472A1 (en) | 2012-12-14 | 2014-06-19 | Takeda Vaccines, Inc. | Compositions, methods of administration and uses for trivalent dengue virus formulations |
| ES2933970T3 (es) | 2013-03-15 | 2023-02-15 | Takeda Vaccines Inc | Composiciones y métodos para construcciones quiméricas de virus del dengue en vacunas |
| SG10201807826XA (en) | 2014-02-11 | 2018-10-30 | Massachusetts Inst Technology | Novel full spectrum anti-dengue antibody |
| GB201704126D0 (en) * | 2017-03-15 | 2017-04-26 | Blom Nihlén Kim Andrea | Vaccine |
| EP3601543A4 (en) * | 2017-03-30 | 2021-01-27 | Merck Sharp & Dohme Corp. | ADDING NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND RELEASE OF HOST CELL NUCLEIC ACIDS |
| SG11202002933TA (en) | 2017-10-05 | 2020-04-29 | Sanofi Pasteur | Compositions for booster vaccination against dengu |
| CA3111332A1 (en) | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| AU2020331884B2 (en) | 2019-08-16 | 2025-01-23 | Takeda Vaccines, Inc. | Methods for preventing dengue and Hepatitis A |
| EP4110381A1 (en) | 2020-02-27 | 2023-01-04 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| WO2023147342A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| EP4479025A1 (en) | 2022-02-15 | 2024-12-25 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| WO2023215383A1 (en) | 2022-05-04 | 2023-11-09 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| WO2024108087A1 (en) | 2022-11-18 | 2024-05-23 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
| WO2024118740A1 (en) | 2022-11-29 | 2024-06-06 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2025072259A1 (en) | 2023-09-25 | 2025-04-03 | Takeda Vaccines, Inc. | Coadministration of tetravalent dengue vaccine with hpv vaccine |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US6676936B1 (en) * | 1988-07-14 | 2004-01-13 | The United States Of America As Represented By The Department Of Health And Human Services. | Chimeric and/or growth-restricted flaviviruses |
| US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| US7192593B2 (en) * | 1997-05-23 | 2007-03-20 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens |
| US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| AU1813901A (en) * | 1999-12-01 | 2001-06-12 | Oravax, Inc | Chimeric flavivirus vaccines |
| AU2003239932A1 (en) * | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| US6966281B1 (en) * | 2004-05-05 | 2005-11-22 | Hale James R | Internal combustion device and methods of use |
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
-
2006
- 2006-08-09 AU AU2006280144A patent/AU2006280144B2/en not_active Ceased
- 2006-08-09 CA CA002618783A patent/CA2618783A1/en not_active Abandoned
- 2006-08-09 JP JP2008526124A patent/JP5227172B2/ja not_active Expired - Fee Related
- 2006-08-09 WO PCT/US2006/030846 patent/WO2007021672A2/en not_active Ceased
- 2006-08-09 EP EP06800943A patent/EP1924280A4/en not_active Ceased
- 2006-08-09 BR BRPI0614265-6A patent/BRPI0614265A2/pt not_active Application Discontinuation
- 2006-08-09 US US12/063,365 patent/US20080193477A1/en not_active Abandoned
- 2006-08-10 AR ARP060103502A patent/AR055603A1/es unknown
- 2006-08-10 MY MYPI20063881 patent/MY151051A/en unknown
- 2006-08-10 TW TW095129386A patent/TW200740458A/zh unknown
-
2008
- 2008-02-06 IL IL189329A patent/IL189329A/en not_active IP Right Cessation
- 2008-03-04 NO NO20081127A patent/NO20081127L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL189329A0 (en) | 2008-06-05 |
| US20080193477A1 (en) | 2008-08-14 |
| WO2007021672A3 (en) | 2007-11-22 |
| IL189329A (en) | 2015-07-30 |
| BRPI0614265A2 (pt) | 2011-03-22 |
| EP1924280A2 (en) | 2008-05-28 |
| JP2009504654A (ja) | 2009-02-05 |
| CA2618783A1 (en) | 2007-02-22 |
| AU2006280144B2 (en) | 2012-06-14 |
| AR055603A1 (es) | 2007-08-29 |
| TW200740458A (en) | 2007-11-01 |
| AU2006280144A1 (en) | 2007-02-22 |
| MY151051A (en) | 2014-03-31 |
| EP1924280A4 (en) | 2008-12-10 |
| WO2007021672A2 (en) | 2007-02-22 |
| NO20081127L (no) | 2008-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5227172B2 (ja) | デングウイルス感染に対するワクチン接種 | |
| JP6830118B2 (ja) | ワクチン組成物 | |
| Guirakhoo et al. | Live attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all | |
| RU2376374C2 (ru) | Вакцина против вируса лихорадки западного нила | |
| US20150265695A1 (en) | Vaccine compositions for prevention against dengue virus infection | |
| US9861692B2 (en) | Dengue virus vaccine compositions and methods of use thereof | |
| US10449243B2 (en) | Dengue virus vaccine compositions and methods of use thereof | |
| Cheong et al. | Zika virus vaccine: the current state of affairs and challenges posed by antibody-dependent enhancement reaction | |
| US10716843B2 (en) | Immune enhancing recombinant dengue protein | |
| CN101287490B (zh) | 对抗登革热病毒感染的疫苗接种 | |
| MX2008001978A (en) | Vaccination against dengue virus infection | |
| AU2012216852A1 (en) | Vaccination against dengue virus infection | |
| HK1212906B (en) | Vaccine compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090803 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100629 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111226 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120323 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120330 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120625 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130213 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130315 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160322 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |